Apparatus

Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!

As more and more organisms become resistant to antibiotics, the threat to human health is increasing. The overuse of antibiotics leads to drug resistance. It is very important to limit the use of antibiotics. The research team of the University of Alberta in Canada has recently developed a hand-held detection instrument, which allows first-line clinicians to distinguish between patients with viral infection or bacterial infection within a few minutes, thus helping to reduce unnecessary antibiotic prescriptions and overuse of antibiotics. Because antibiotics are only effective for bacteria, if the patient is infected with virus, there is no need to prescribe antibiotics.

Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.

Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).

The collaboration aims to improve the efficiency of the drug discovery pipeline by leveraging industry-leading capabilities to identify genetic variants that cause human disease.

The "me better" strategy has always been a great story for pharmaceutical companies.

When it comes to the breath detector, everyone will think of the thing used by the traffic police to check drinking and driving. For those who drink and drive, they will lose their temper when they see the breath detector. In fact, the gas exhaled by the human body has many characteristics. It can not only detect alcohol, but also reflect the health of the human body and detect some diseases. This breath detector introduced in this article can detect breast cancer, diabetes, lung cancer, Parkinson's disease, asthma, schizophrenia, kidney and liver failure and other diseases.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."

The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.